MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers

MiR-138 是癌症中异质性 MYC 转录本群的强效调节剂

阅读:6
作者:Ng Desi, Velda Teh, Qing Yun Tong, Chun You Lim, Hossein Tabatabaeian, Xiao Hong Chew, Avencia Sanchez-Mejias, Jia Jia Chan, Bin Zhang, Priyankaa Pitcheshwar, Bei-En Siew, Shi Wang, Kuok-Chung Lee, Choon-Seng Chong, Wai-Kit Cheong, Bettina Lieske, Ian Jse-Wei Tan, Ker-Kan Tan, Yvonne Tay

Abstract

3'UTR shortening in cancer has been shown to activate oncogenes, partly through the loss of microRNA-mediated repression. This suggests that many reported microRNA-oncogene target interactions may not be present in cancer cells. One of the most well-studied oncogenes is the transcription factor MYC, which is overexpressed in more than half of all cancers. MYC overexpression is not always accompanied by underlying genetic aberrations. In this study, we demonstrate that the MYC 3'UTR is shortened in colorectal cancer (CRC). Using unbiased computational and experimental approaches, we identify and validate microRNAs that target the MYC coding region. In particular, we show that miR-138 inhibits MYC expression and suppresses tumor growth of CRC and hepatocellular carcinoma (HCC) cell lines. Critically, the intravenous administration of miR-138 significantly impedes MYC-driven tumor growth in vivo. Taken together, our results highlight the previously uncharacterized shortening of the MYC 3'UTR in cancer, and identify miR-138 as a potent regulator of the heterogenous MYC transcript population.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。